Ying-Tao Lin (Yingtao Lin)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 4

Top Topics

Decision Making

Squamous Cell Carcinoma

Health Insurance

Small Cell Lung Cancer

Top Venues

Risk management and healthcare policy

Cancer management and research

International journal of clinical pharmacy

This page only lists publications with an associated author ORCID identifier.

Publications

Jingxuan Wei, Kai Xu, Ying-Tao Lin, Qiang Liu, Chongchong Zhou, Pei Zhang, Rui Ma, Mengdie Zhang, Lingli Zhang, Xin Li
Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China. International journal of clinical pharmacy (2024)
Linlin Shang, Ying-Tao Lin, Wenqing Fang, Yanyan Liu, Yuwen Bao, Xin Li, Yuanyuan Zhang
How National Health Insurance Coverage Policy Affected the Use of Trastuzumab and Rituximab in China: A Bicentric Retrospective Study. Risk management and healthcare policy 16 (2023)
Chongchong Zhou, Jingxuan Wei, Kai Xu, Ying-Tao Lin, Lingli Zhang, Xin Li
Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China. Risk management and healthcare policy 16 (2023)
Ying-Tao Lin, Ying Chen, Tian-Xiu Liu, Fang Kuang, Ping Huang
Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma. Cancer management and research 13 (2021)